Systematic review of use of β-blockers in sepsis

Journal of Anaesthesiology Clinical Pharmacology

Volumn 31, Issue 4, 2015, Pages 460-465

  Chacko, Cyril Jacob ^a   Gopal, Shameer ^a  

^a ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

cardiac index; heart rate control; mortality; sepsis; systematic review; blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NORADRENALIN;

ACID BASE BALANCE; BRADYCARDIA; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG ACTIVITY; DRUG USE; DRUG WITHDRAWAL; HEART INDEX; HEART RATE; HEART STROKE VOLUME; HEMODYNAMIC PARAMETERS; HUMAN; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW;

EID: 84948450959     PISSN: 09709185     EISSN: 22312730     Source Type: Journal    
DOI: 10.4103/0970-9185.169063     Document Type: Review

References (31)

1. Carlson DL, Willis MS, White DJ, Horton JW, Giroir BP. Tumor necrosis f actor-alpha-induced caspase activation mediates endotoxin-related cardiac dysfunction. Crit Care Med 2005;33:1021-8.
2. Aboab J, Sebille V, Jourdain M, Mangalaboyi J, Gharbi M, Mansart A, et al. Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock. Intensive Care Med 2011;37:1344-51.
3. Suzuki T, Morisaki H, Serita R, Yamamoto M, Kotake Y, Ishizaka A, et al. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005;33:2294-301.
4. Hagiwara S, Iwasaka H, Maeda H, Noguchi T. Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock 2009;31:515-20.
5. Higgins JP, Green S. Cochrane Hand Book for Systematic Review of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. Available from: http://www.cochrane-handbook.org. [Last accessed on 2014 Feb 24; Last updated on 2011 Mar].
6. Available from: http://www.clinicaltrials.gov. [Last accessed on 2014 Jan 25].
7. Morelli A, Ertmer C, Rehberg S, Orecchioni A, Cecchini V, Di Russo A, et al. Heart rate control with esmolol in septic shock: A randomized controlled trial. Intensive Care Med 2011;37:0342.
8. Balik M, Rulisek J, Leden P, Zakharchenko M, Otahal M, Bartakova H. Is cardioprotective beta blockade feasible in severe sepsis? A pilot study. Intensive Care Med 2011;37:0342.
9. Berk JL, Hagen JF, Dunn JM. The role of beta adrenergic blockade in the treatment of septic shock. Surg Gynecol Obstet 1970;130:1025-34.
10. Christensen S, Johansen MB, Tønnesen E, Larsson A, Pedersen L, Lemeshow S, et al. Preadmission beta-blocker use and 30-day mortality among patients in intensive care: A cohort study. Crit Care 2011;15:R87.
11. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: A randomized clinical trial. JAMA 2013;310:1683-91.
12. Macchia A, Romero M, Comignani PD, Mariani J, D'Ettorre A, Prini N, et al. Previous prescription of ß-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med 2012;40:2768-72.
13. Gutierrez J, Hossam A, Lazarezcu R, Kay E, Rundek T. Effect of beta blockers on sepsis outcome. Med Sci Monit 2009;15:CR499-503.
14. Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, et al. Microvascular effects of heart rate control with esmolol in patients with septic shock: A pilot study. Crit Care Med 2013;41:2162-8.
15. Schmittinger CA, Dünser MW, Haller M, Ulmer H, Luckner G, Torgersen C, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care 2008;12:R99.
16. Balik M, Rulisek J, Leden P, Zakharchenko M, Otahal M, Bartakova H, et al. Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Wien Klin Wochenschr 2012;124:552-6.
17. Berk JL, Hagen JF, Maly G, Koo R. The treatment of shock with beta adrenergic blockade. Arch Surg 1973;104:46-51.
18. Misonoo Y, Yajima S, Morisaki H, Suzuki T, Takeda J. Efficacy and safety of beta1 adrenoreceptor blockade by landiolol in sepsis. Crit Care Med 2009;37/12.
19. Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery 2006;139:686-94.
20. Sander O, Welters ID, Foëx P, Sear JW. Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med 2005;33:81-8.
21. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-9.
22. Tuman KJ, McCarthy RJ. Individualizing beta-adrenergic blocker therapy: Patient-specific target-based heart rate control. Anesth Analg 1999;88:475-6.
23. Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: Adverse effects of adrenergic stress. J Intensive Care Med 2009;24:293-316.
24. Schmittinger CA, Torgersen C, Luckner G, Schröder DC, Lorenz I, Dünser MW. Adverse cardiac events during catecholamine vasopressor therapy: A prospective observational study. Intensive Care Med 2012;38:950-8.
25. Novotny NM, Lahm T, Markel TA, Crisostomo PR, Wang M, Wang Y, et al. beta-Blockers in sepsis: Reexamining the evidence. Shock 2009;31:113-9.
26. Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med 2001;345:1223-9.
27. de Montmollin E, Aboab J, Mansart A, Annane D. Bench-tobedside review: Beta-adrenergic modulation in sepsis. Crit Care 2009;13:230.
28. Muthu K, Deng J, Romano F, He LK, Gamelli R, Shankar R, et al. Thermal injury and sepsis modulates beta-adrenergic receptors and cAMP responses in monocyte-committed bone marrow cells. J Neuroimmunol 2005;165:129-38.
29. Hjemdahl P, Larsson PT, Wallén NH. Effects of stress and beta-blockade on platelet function. Circulation 1991;84 6 Suppl:VI44-61.
30. Markel A, Brook JG, Levy Y, Aviram M, Youdim MB. Increased platelet adhesion and aggregation in hypertensive patients: Effect of atenolol. Br J Clin Pharmacol 1983;16:663-8.
31. Ackland GL, Yao ST, Rudiger A, Dyson A, Stidwill R, Poputnikov D, et al. Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats. Crit Care Med 2010;38:388-94.